Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

This study details the isolation and characterization of the human type II 5 alpha-reductase gene, which may play a role in male pseudohermaphroditism, prostate cancer, and benign prostatic hyperplasia.

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.

This chapter reviews the male accessory sex glands in rats and their responses to hormonal influences, detailing common spontaneous changes and effects of compounds, but it provides no new experimental findings.

Statins do not impact BPH and LUTS progression when combined with finasteride.

Hair loss can be an early sign of prostate enlargement.

This analysis concluded that finasteride effectively reduces prostate size and urinary symptoms in benign prostatic hyperplasia, offering a favorable safety profile and versatility as a treatment option.

This report presents a case of familial male-limited precocious puberty with a novel LHCGR gene mutation, where a boy responded well to treatment with bicalutamide and anastrozole.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This review discusses the role of finasteride preoperatively in reducing bleeding and complications during TURP and reports no new clinical results; the authors emphasize its potential benefits based on existing studies.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This review explores the potential impact of hormonal changes during aging on benign prostate hyperplasia-related urinary symptoms and metabolic syndrome, highlighting the hypothesis of a male PCOS-equivalent but reports no new clinical results.

This study found that 44.3% of patients with benign prostatic hyperplasia experienced high anxiety levels, which were significantly associated with residual symptoms and demographic factors.

This article discusses methods to enhance finasteride delivery to scalp skin using heat and chemical penetration enhancers and reports no new experimental findings.

This study found that finasteride-loaded microemulsions using poloxamer 124 significantly enhanced skin penetration of the drug compared to a standard solution, primarily through targeting hair follicles via the transfollicular pathway, with intercluster, intercellular, and transcellular pathways contributing less.

This study found that prolonged acute tissue expansion notably increased the amount of scalp tissue removed during scalp reduction surgery in three patients.

Finasteride and dutasteride can affect sexual function in BPH patients.

This study found that dermal papilla cells from beard and axillary hair follicles can produce androgen-dependent factors that stimulate proliferation in adjacent follicular epithelial cells under testosterone influence.

This case report details a diagnostic challenge in a postmenopausal woman with severe hyperandrogenism where distinguishing between adrenal and ovarian causes was complicated by elevated 17-OH Progesterone and asymmetric ovarian enlargement; pending surgical pathology is expected to guide further management.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

This review discusses the sexual side effects of medical and surgical treatments for benign prostatic hyperplasia, such as erectile dysfunction and changes in ejaculation, but presents no new clinical findings.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This study found that frailty independently raises the risk of clinical BPH progression and serious adverse events in older men, suggesting that shared decision-making is essential when considering medical therapy for frail patients.